Several small-molecule drugs and immunotherapies have been approved for liver cancer. But the lack of response in some patients—and potential side effects—underline the need for new treatments. Now, a Swiss team has designed a gene therapy that, by processing multiple cellular cues, precisely targeted liver cancer in mice.

Medtronic is scrambling to address a host of quality control concerns raised by the FDA in a warning letter that followed an inspection of its Northridge, California, facility.

Eli Lilly will ask the FDA to approve its IL-23 drug mirikizumab in ulcerative colitis next year after passing a phase 3 test in the inflammatory bowel disease.

Galera’s shares were pummeled in the wake of news that its radiotherapy complication drug flunked a phase 3 study, but now the biotech says the study results were in error, and the treatment did, in fact, work.

When Hong Kong venture capital firm ORI Capital poured $30 million into CAR-T developer AffyImmune Therapeutics in October, the VC firm’s founder Simone Song cited more than a half-dozen obstacles facing AffyImmune and other biopharmas seeking to translate CAR-T technology to solid tumors.

Nearly two years after BrainsGate submitted its implantable neurostimulation device for FDA premarket approval, an advisory panel for the agency struck a major blow to the Israeli company’s plans.

Takeda is looking for its next shot at multiple myeloma beyond Velcade and is now previewing some early data showing partial responses in 38% of patients in one dose group for the next-in-line candidate modakafusp alfa.

Next-generation sequencing has revolutionized the field of medicine, with labs now able to dig through a patient’s entire genome to locate even the tiniest indicators of disease. And while this technology works remarkably fast compared to traditional diagnostic methods, it still requires quite a bit of dedicated time and effort to prepare DNA samples for processing.

Philips is looking to bolster its vascular franchise by absorbing Vesper Medical, maker of stents designed to open up blocked or narrowed veins in the legs.

How do cancer cells travel beyond the primary tumor, stay dormant for years and then suddenly wake up, causing cancer to recur? Researchers at Mount Sinai believe they may have found one answer—and that the discovery could offer new tools for predicting and preventing cancer relapses.